CervoMed Names Joshua Boger as New Board Chair
Company Announcements

CervoMed Names Joshua Boger as New Board Chair

CervoMed (CRVO) has released an update to notify the public and investors about its officers.

CervoMed Inc. has appointed the accomplished Joshua S. Boger, Ph.D., founder of Vertex Pharmaceuticals, as its new Chair of the Board and director. With an illustrious background including leadership roles at Vertex and Merck, as well as his current position at Alkeus Pharmaceuticals, Dr. Boger brings a wealth of experience to CervoMed. He holds a significant stake in the company, with shares and warrants just shy of 10%, further tying his interests to the company’s success following a recent merger. In recognition of his new role, Dr. Boger will receive an option grant for 10,000 shares, aligning his compensation with the performance of the company’s stock.

For further insights into CRVO corporate activity, check out TipRanks’ Insiders Trading Activity page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyCervoMed to present on neflamapimod as DLB treatment at CTAD
TheFlyCervoMed initiated with a Buy at Chardan
TipRanks Auto-Generated NewsdeskCervoMed Updates Investors on Business and Clinical Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App